Takeda TAK-003 Wins India Dengue Vaccine Nod
Takeda dengue vaccine India DCGI authorization makes TAK-003 the country's first approved dengue shot. Takeda said on July 21, 2026 that India's Drug Controller General cleared the live attenuated tetravalent vaccine for ages 4 to 60, without requiring pre-vaccination serostatus testing.
Contents10 sections
Key Takeaways
- DCGI granted TAK-003 marketing authorization in India for ages 4–60 regardless of prior dengue exposure.
- India is now among regional markets where TAK-003 is approved, joining Indonesia, Thailand, Malaysia, and Vietnam.
- Evidence includes a local Phase 3 study and the global TIDES pivotal program with multi-year protection data.
- WHO SAGE has endorsed use without pre-vaccination screening; the vaccine holds WHO prequalification.
TAK-003 in India at a glance
| Field | Detail |
|---|---|
| Vaccine | TAK-003 (dengue tetravalent vaccine, live attenuated) |
| Company | Takeda |
| Regulator | Drug Controller General of India (DCGI) |
| Action | Marketing authorization announced July 21, 2026 |
| Age range | 4 to 60 years |
| Pre-test | Not required; approved regardless of prior dengue exposure |
| Global footprint | 43 country approvals; >32 million doses distributed (company) |
What did DCGI authorize?
Takeda said DCGI granted marketing authorization for TAK-003 to prevent dengue disease in individuals 4 to 60 years of age. The label, as described by the company, does not require pre-vaccination testing and covers people regardless of previous dengue exposure—India's first dengue vaccine approval.
See Takeda's July 21 PR Newswire India approval release.
Why does India matter for dengue prevention?
Takeda cited an 11-fold rise in reported dengue cases in India over two decades and more than 233,000 reported cases in 2024, while modeling suggests tens of millions of infections annually. Transmission is no longer limited to monsoon months in several states, spanning urban and rural areas.
Global risk mapping context is summarized in our related note on areas with dengue risk and CDC map criteria.
What clinical program underpins the India nod?
Approval is supported by a local Phase 3 study and the pivotal Phase 3 TIDES trial, which Takeda called the largest and longest dengue-vaccine efficacy study. The company said TIDES showed sustained protection against dengue and dengue-related hospitalization with a favorable safety profile, and cited seven-year data covering all four serotypes.
- Live-attenuated dengue serotype 2 genetic backbone for all four serotypes
- WHO SAGE endorsement since 2023 for use without pre-vaccination screening
- WHO prequalification enabling UNICEF/PAHO procurement pathways
WHO immunization advisory context is on the WHO Strategic Advisory Group of Experts on Immunization (SAGE) pages.
What comes next for access in India?
Takeda said it will work with Indian regulators, public-health stakeholders, and providers on planning, delivery, and availability after the DCGI decision. Public-program inclusion, pricing, and state rollout timelines were not specified in the announcement.
What remains uncertain?
Exact TIDES efficacy percentages by serotype and age band for the India label belong in the local prescribing information, not the launch wire. National immunization program uptake, private-market pricing, and cold-chain capacity will determine real-world impact. Vaccine effectiveness against evolving circulating genotypes needs post-marketing surveillance.
Related NovaPharma coverage
- Piyush Goyal Invites Global Pharma Firms to Partner With India
- Childhood Vaccine Schedule EO: Pharma Impact
- Building a Smarter Medical Devices Ecosystem in India
Frequently Asked Questions
What dengue vaccine did India approve?
On July 21, 2026, Takeda said India's Drug Controller General of India granted marketing authorization for TAK-003 for prevention of dengue disease in people 4 to 60 years of age, regardless of prior dengue exposure and without pre-vaccination testing. It is India's first approved dengue vaccine.
What evidence supports TAK-003 in India?
Takeda said the India approval rests on a local Phase 3 study plus the pivotal global TIDES Phase 3 program, which showed sustained protection against dengue and dengue-related hospitalization with a favorable safety profile. The company also cited seven-year follow-up data across all four serotypes.
Where else is TAK-003 approved in Asia?
Besides India, Takeda said TAK-003 is approved in Indonesia, Thailand, Malaysia, and Vietnam. Globally it has approvals in 43 countries with more than 32 million doses distributed since the 2022 launch, and it holds WHO prequalification.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for TAK-003.
Unlock full calendar →Takeda pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
